Study re: Improved Survival in Oligometastatic Pts.

Just a heads-up about a fascinating study:

OligoMetastasis (OM) in breast cancer is usually characterized by a solitary lesion or a few detectable lesions (tumors).These lesions are generally limited to a single organ, in which local therapy (possibly along with systemic therapy) with curative intent could impact survival in a positive manner. This population of "potentially curable" MBC patients is estimated to represent 1% to-10% of newly diagnosed patients with MBC. A multimodal approach is endorsed for this group. Patients with OM disease can be divided into 3 subtypes:

-Those who initially present with Oligometastasis

-Those with residual Oligometastasis after Systemic Therapy (ST)

-Those with relapsed Oligometastasis after curative locoregional therapy

In the first randomized Phase 2 clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live, and that it doubles how long they may live without cancer.In this recent study, 99 patients with various types of metastatic cancers were either treated with palliative standard of care radiation therapy, or with stereotactic ablative radiotherapy (also known as stereotactic body radiation therapy [SBRT] - a form of high-precision cancer therapy that delivers substantially higher doses of radiation to the tumor site in just one or a few treatment sessions).Patients who received SBRT treatments lived considerably longer than those who did not.Median overall survival (OS) was 41 months (upper limit not yet reached) for patients given stereotactic radiation, compared to 28 months in the standard treatment arm. Furthermore, nearly half (46%) of the patients treated with stereotactic radiation were still alive after five years, compared to 24% in the control group. Stereotactic radiation also doubled the time patients lived without cancer growth. Progression-free survival (PFS) was 12 months in the SBRT arm, compared to 6 months for those who received standard radiation therapy. From: https://www.eurekalert.org/pub_releases/2018-10/asfr-hrt101618.php

Thank you!